Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | unknown | Phase 1 / Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | unknown | Phase 1 | 72 | Caribou Biosciences, Inc.INDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT05628870 | A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer | unknown | Phase 1 | 102 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06724835 | Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) | unknown | Phase 1 | 18 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06585527 | Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma | unknown | Phase 1 | 30 | Beijing Neurosurgical InstituteOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT01818323 | Phase I Trial: T4 Immunotherapy of Head and Neck Cancer | unknown | Phase 1 | 30 | King's College LondonOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06590194 | PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 96 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT03557619 | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies | unknown | Phase 1 | 12 | AbbVieINDUSTRY | 2 | Aug 29, 2024 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06471673 | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | unknown | Phase 1 / Phase 2 | 18 | BriaCell Therapeutics CorporationINDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT05222087 | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study(PRIME_LUNG) | unknown | Phase 1 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05684731 | Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer(K19017-004) | unknown | Phase 1 | 30 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06551233 | Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) | unknown | Phase 1 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06341309 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06545630 | Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases | unknown | Phase 1 | 10 | West China HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03631953 | Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas(ALTREM) | unknown | Phase 1 | 25 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06536712 | Effects of Exosome Adminstration in Preventing Early Leakage in Rectal Cancer Patients Undergoing Low Anterior Resection | unknown | Phase 1 | 20 | Tehran University of Medical SciencesOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04220944 | Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | unknown | Phase 1 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04454476 | Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor | unknown | Phase 1 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06526832 | A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer | unknown | Phase 1 | 9 | BioSyngen Pte LtdINDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06527495 | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 150 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05842785 | TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | unknown | Phase 1 / Phase 2 | 162 | Tyligand Bioscience (Shanghai) LimitedINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04823403 | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma(HIPANIV) | unknown | Phase 1 | 27 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06520319 | Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05803928 | Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies | unknown | Phase 1 | 70 | Hua LiOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT06256055 | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors | unknown | Phase 1 | 24 | UTC Therapeutics Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06109207 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503211 | On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma | unknown | Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 4, 2025source: clinicaltrials